Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance oncology and metabolic disease research, has unveiled plans to increase focus on the life science division of the organization.


CrownBio's life science division currently provides more than one hundred products across a portfolio of antibodies for in vivo and in vitro studies, recombinant proteins, recombinant cell lines, tumor samples for oncology research and drug development, immune checkpoint antibodies, and tumor tissue microarrays. Driven by market demand, CrownBio is investing in expanding the division and forecasts triple digit growth in 2017. The investment includes an addition to the leadership team with the appointment of Debby Saunders, as executive director of life science development.

In support of the expansion in 2017, CrownBio says it will more than double their offering of recombinant cell lines covering important targets and pathways in oncology. Further expansion of CrownBio's product catalog includes tumor tissue microarrays, allowing for rapid assay screening of molecular targets and diagnostic and prognostic markers, as well as high quality immune checkpoint antibodies to detect immune regulators, some of which will be suitable for in vivo use.

"This investment in new products and leadership demonstrates our ongoing commitment to bring to market an expanding toolset to help advance the rate of scientific breakthrough for oncology drug discovery and development,” said Laurie Heilmann, senior vice president, global strategy, marketing and business development, CrownBio.